SG Americas Securities LLC Has $627,000 Holdings in GSK PLC Sponsored ADR $GSK

SG Americas Securities LLC lessened its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 51.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,363 shares of the pharmaceutical company’s stock after selling 11,905 shares during the quarter. SG Americas Securities LLC’s holdings in GSK were worth $627,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Nations Financial Group Inc. IA ADV lifted its holdings in shares of GSK by 11.3% during the first quarter. Nations Financial Group Inc. IA ADV now owns 14,400 shares of the pharmaceutical company’s stock valued at $795,000 after acquiring an additional 1,458 shares during the period. Union Savings Bank bought a new stake in shares of GSK in the 4th quarter worth about $140,000. DGS Capital Management LLC increased its position in shares of GSK by 9.9% during the 4th quarter. DGS Capital Management LLC now owns 39,934 shares of the pharmaceutical company’s stock worth $1,958,000 after purchasing an additional 3,592 shares in the last quarter. SkyView Investment Advisors LLC acquired a new stake in shares of GSK during the 4th quarter worth about $302,000. Finally, IHT Wealth Management LLC lifted its holdings in GSK by 1.3% during the 4th quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock valued at $736,000 after purchasing an additional 188 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. HSBC upgraded shares of GSK from a “reduce” rating to a “hold” rating in a research note on Monday. Weiss Ratings downgraded GSK from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 11th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $53.00.

GSK Trading Up 0.3%

Shares of NYSE GSK opened at $53.23 on Wednesday. GSK PLC Sponsored ADR has a 1-year low of $35.45 and a 1-year high of $61.69. The company has a market cap of $107.81 billion, a PE ratio of 13.83, a P/E/G ratio of 3.41 and a beta of 0.35. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average of $51.49 and a two-hundred day moving average of $53.18.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be given a $0.44 dividend. This represents a $1.76 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, May 15th. GSK’s payout ratio is 47.01%.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.